- Home
- /
- Therapeutic Expertise
- /
- Oncology & Hematology
Oncology & Hematology
Partnering to overcome the complex challenges in Oncology & Hematology Research
Tailoring approaches to diverse cancer types, aligning patient recruitment with treatment paths, adapting to evolving science, and ensuring consistent, efficient trial management worldwide are key factors. At Lambda, we embody the necessary expertise and dedication to excel across all aspects of oncology clinical development.
Our team possesses in-depth knowledge of both traditional and cutting-edge therapies, allowing us to navigate a wide spectrum of indications—from solid tumors to hematological malignancies. This encompasses promising therapeutic approaches like molecularly targeted agents, immunotherapies, cell and gene therapies, and innovative combinations. Whether addressing advanced solid tumors or hematological malignancies, we are committed to relentless efforts to uncover potential breakthroughs and provide hope to patients globally.
Oncology Imaging:
Our experts excel in oncology imaging, conducting independent assessments of solid tumors and lymphomas in line with RECIST 1.1 and Cheson criteria. We adeptly handle various modalities including CT, PET-CT, and MRI. Our extensive experience in oncology imaging covers over 20+ studies in Metastatic Breast Cancer, Non-Small Cell Lung Cancer, Prostate Cancer, Head & Neck Cancer, Gastric Cancer, and Ovarian Cancer.
Our expertise extends to managing various Oncology indications, including but not limited to:
- Breast Cancer
- Malignant Gliomas
- Advance Prostate Cancer
- Myelodysplastic Syndrome
- Metastatic Colorectal Cancer
- Metastatic Gastric Adenocarcinoma
- Solid Tumors with Bone Metastases
- Recurrent Metastatic Ovarian Carcinoma
- Acute Myeloid Leukemia in Remission Phase
- Platinum Resistant or Refractory Ovarian Cancer
- Glioblastoma Multiforme or Anaplastic Astrocytoma
- Pediatric Cancer Patients on Oral Cyclophosphamide Treatment
- Inoperable Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
- Ovarian Cancer
- Advanced Solid Tumors
- Chronic Myeloid Leukemia
- Non-Hodgkin's Lymphoma
- Advanced Solid Malignancies
- Non-Muscle Invasive Bladder Cancer
- Triple negative breast cancer (TNBC)
- Pediatric Patients with Malignant Gliomas
- Chronic Idiopathic Thrombocytopenic Purpura
- Metastatic Castration-Resistant Prostate Cancer
- Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Chronic Refractory Immune (Idiopathic) Thrombocytopenic Purpura
- Rhabdomyosarcoma or Wilms’ Tumor on Myelosuppressive Chemotherapy (CmT) Regimen
- Pancreatic Cancer
- Advanced Breast Cancer
- Metastatic Breast Cancer
- Multiple Cancer Indications
- Metastatic Positive Breast Cancer
- Non-Small Cell Lung Cancer Patients
- Metastatic Small Cell Lung Cancer (SCLC)
- Chronic Primary Immune Thrombocytopenia
- Bone Metastases from Advanced Malignancies
- Oral Mucositis in Patients with Head & Neck Cancer
- Philadelphia Chromosome Positive Chronic Myeloid Leukemia
- Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Our Presence
We are aggressively expanding globally and are confident in our research initiatives, propelling us toward a trajectory of excellence.
Corporate Office – Ahmedabad
Lambda House, Plot No. 38,
Survey No. 388, Near Silver Oak University,
S.G. Highway, Gota, Ahmedabad - 382481,
Gujarat, India.
Representative Office
Poland (Warsaw)
Representative Office
UK (London)
Representative Office
Canada (Toronto)
Representative Office
Pittsburgh
Representative Office
US (Las Vegas)
Let's Unveil New Therapies Together
Connect with our experts to leverage our proven track record of clinical research excellence.